VIR earnings analysis
What we found in VIR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Vir Biotechnology's Q1 2026 report reveals a significant downturn, reporting revenue of -$29,000 against expectations of $122.5 million, coupled with an EPS loss of $0.85, substantially below the estimated $0.38. Despite the disappointing results, the company maintains a robust cash position of $809.3 million, sufficient to fund operations into the latter half of 2028, and is actively progressing in clinical trials for its therapies targeting infectious diseases and cancer.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Miss
- Reported revenue of -$29,000 against an estimate of $122.5 million.
- Substantial EPS Loss
- Actual EPS of -0.85 far exceeded the estimated EPS of 0.38.
- Strong Cash Position
- Cash, cash equivalents, and investments totaled $809.3 million as of March 31, 2026.
- R&D Expense Decrease
- R&D expenses fell to $108.9 million from $118.6 million year-over-year.
- Collaboration Agreement with Astellas
- Secured a $240 million upfront cash payment from Astellas for the collaboration on VIR-5500.
- Liquidity Outlook Positive
- Company expects existing resources to fund operations through at least 2028.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increasing Net Loss
- Net loss widened to $125.7 million in Q1 2026 from a loss of $120.9 million in Q1 2025.
- Regulatory Approval Challenges
- Future success substantially depends on timely clinical development, which may face unforeseen challenges.
- Uncertain Revenue Stream
- Company does not expect significant revenue until regulatory approvals, with ongoing reliance on grants and collaborations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.85
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VIR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever